High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL Meeting Abstract


Authors: Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; Jackson, C.; Shukla, N.; Spitzer, B.; Prockop, S.; Steinherz, P. G.; Kung, A. L.; O'Reilly, R. J.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
Abstract Title: High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419403150
PROVIDER: wos
Notes: Meeting Abstract: 1326 -- Source: Wos
MSK Authors
  1. Nancy Kernan
    434 Kernan
  2. Farid Boulad
    281 Boulad
  3. Susan E Prockop
    186 Prockop
  4. Renier J Brentjens
    231 Brentjens
  5. Kevin Joseph Curran
    73 Curran
  6. Jae Hong Park
    178 Park
  7. Craig Steven Sauter
    199 Sauter
  8. Michel W J Sadelain
    486 Sadelain
  9. Isabelle C Riviere
    189 Riviere
  10. Peter G Steinherz
    190 Steinherz
  11. Richard O'Reilly
    576 O'Reilly
  12. Neerav Shukla
    86 Shukla
  13. Barbara Spitzer
    35 Spitzer
  14. Eric Smith
    48 Smith
  15. Maria   Cancio
    15 Cancio
  16. Andrew L Kung
    36 Kung